

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
M078476

In Re Application Of: **Marta I. Rendon**

Serial No.
TBD

Filing Date
Herewith

Examiner
TBD

Group Art Unit
TBD

Title: **Method and Topical Composition for Treatment of Hyperpigmented Skin**

Address to:

**Assistant Commissioner for Patents
Washington, D.C. 20231**

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
M078476

In Re Application Of: **Marta I. Rend n**

Serial No.
TBD

Filing Date
Herewith

Examiner
TBD

Group Art Unit
TBD

Title: **Method and Topical Composition for Treatment of Hyperpigmented Skin**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **50-1731** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

***This certificate may only be used if paying by deposit account.**

Dated: **7-21-03**



Signature

Patricia E. McQueeney
Reg. No. 49,083
Becker & Poliakoff, P.A.
3111 Stirling Road
Fort Lauderdale, FL 33312
(954) 364-6006

CC:

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. M078476		SERIAL NO. TBD	
				Marta I. Rendon			
				FILING Herewith		GROUP TBD	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	AA	DOCUMENT NUMBER 5,053,230	DATE 10/01/1991	NAME Gazzani	CLASS --	SUBCLASS --	FILING DATE IF APPROPRIATE --
	AB	5,116,605	05/26/1992	Alt	--	--	--
	AC	5,202,313	04/13/1993	Bombardelli et al.	--	--	--
	AD	5,268,176	12/07/1993	Znaiden et al.	--	--	--
	AE	5,358,716	10/25/1994	Laugier et al.	--	--	--
	AF	5,391,550	02/21/1995	Carniglia et al.	--	--	--
	AG	5,556,887	09/17/1996	Lerner	--	--	--
	AH	5,607,980	03/04/1997	McAtee et al.	--	--	--
	AI	5,637,304	06/10/1997	Salini	--	--	--
	AJ	5,665,364	09/09/1997	McAtee et al.	--	--	--
	AK	5,738,856	04/14/1998	Korb et al.	--	--	--
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	AL	ABSTRACT - Sasson et al.; Growth and Bone Mineralisation as Affected by Dietary Calcium, Phytic Acid and Vitamin D; Comp Biochem Physiol A; 72(1); 01-Jan-1982; pp. 43-48.					
	AM	ABSTRACT - MacFoy et al.; Medicinal Plants in Pujehun District of Sierra Leone; J. Ethnopharmacol.; 8(2); 01-Aug-1983; pp.215-23.					
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. M078476		SERIAL NO. TBD	
				Marta I. Rendon			
				FILING Herewith		GROUP TBD	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AN	5,837,255	11/17/1998	Inman et al.	--	--	--
	AO	5,851,543	12/22/1998	Korb et al.	--	--	--
	AP	5,877,209	03/02/1999	Yunis	--	--	--
	AQ	5,962,517	10/05/1999	Murad	--	--	--
	AR	5,998,485	12/07/1999	Tyan et al.	--	--	--
	AS	6,106,850	08/22/2000	Simon et al.	--	--	--
	AT	6,190,678	02/20/2001	Hasenoehrl et al.	--	--	--
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		AU	ABSTRACT - Jeziorek et al.; A Theoretical Study of the Mechanism of Oxygen Binding by Model Anthraquinones. Part II. Quantum-mechanical studies of the energetics of oxygen binding to model anthraquinones.; Anticancer Drug Des; 8(3); 01-Jun-1993; pp. 223-35.				
		AV	ABSTRACT - Pollack et al.; Mechanism of Inositol Monophosphatase, the Putative Target of Lithium Therapy; Proc Natl Acad Sci USA; 21;91(13) Jun 1994; 5738-9.				
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) M078476	Application Number TBD
		Applicant(s) Marta I. Rendon	
		Filing Date Herewith	Group Art Unit TBD

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
AW	ABSTRACT - Nakagawa et al.; Contact allergy to kojic acid in skin care products; Contact Dermatitis; 32(1); 01-Jan-1995; pp. 9-13.
AX	ABSTRACT - Atack et al.; Inositol Monophosphate - a putative target for Li+ in the treatment of biopolar disorder; Trends Neurosci; 18(8); 01-Aug-1995; pp. 343-9.
AY	ABSTRACT - Kroser et al.; Risk factors for the development of colorectal carcinoma and their modification; Hematol Oncol Clin North Am; 11(4); 01-Aug-1997; pp. 547-77.
AZ	ABSTRACT - Bravo; Acido Kojico: Un Neuvo Despigmentante; Rev. Chilena Dermatol.; 13(3); 1997; pp. 186-9.
BA	ABSTRACT - Pugliese et al.; The Skin's Antioxidant Systems; Dermatol Nurs; 10(6); 01-Dec-1998; pp. 417-8.
BB	ABSTRACT - Fuller et al.; Vismiaphenones D-G, new prenylated benzophenones from Vismia cayennensis; J Nat Prod; 62(1); 01-Jan-1999; pp. 67-9.
BC	ABSTRACT - Lim; Treatment of Melasma using Kojic Acid in a Gel Containing Hydroquinone and Glycolic Acid; Dermatol Surg; 25(4); 01-Apr-1999; pp. 282-4.
BD	ABSTRACT - Jin et al.; Aloesin and arbutin inhibit tyrosinase activity in a synergistic manner via a different mechanism of action; Arch Pharm Res; 22(3); 01-Jun-1999; pp. 232-6.
BE	ABSTRACT - Nickel et al.; Inositol hexaphosphate reduces 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase independent of protein kinase C isoform expression in keratinocytes; Cancer Letters; 140(1-2); 01-Jun-1999; pp. 105-11.
BF	ABSTRACT - Ishikawa et al.; Inhibition of skin cancer by IP6 in vivo: initiation-promotion model; Anticancer Res; 19(5A); Sept. Oct. 1999; pp. 3749-52.
BG	ABSTRACT - Barker et al.; Inositol hexakisphosphate and beta-cell stimulus-secretion coupling; Anticancer Res; 19(5A); Sept. Oct. 1999; pp. 3737-41.
BH	ABSTRACT - Shamsuddin; Metabolism and cellular functions of IP6: a review; Anticancer Res; 19(5A); Sept. Oct. 1999; pp. 3733-6.
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

